ARTICLE | Company News
BioMarin, Ibex deal
October 15, 2001 7:00 AM UTC
BMRN will purchase all pharmaceutical compounds from IBT for $8.5 million in stock and $2 million in cash. In addition, IBT will receive up to $9.5 million upon FDA approval of the acquired products. ...